Cochrane · systematic review · CD003426
Drugs for preventing red blood cell dehydration in people with sickle cell disease
Nagalla, S, Ballas, SK · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Cystic Fibrosis and Genetic DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
6
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 16.7%Low 3 · 50%Moderate 2 · 33.3%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Summary of findings
Population: adults and children with sickle cell disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of deaths | no estimate extracted | 3 studies · 524 participants | Low Downgraded: risk of bias, imprecision |
Number of sickle pain crises | no estimate extracted | 3 studies · 524 participants | Low Downgraded: risk of bias, imprecision |
Number of serious complications of sickle cell disease: mean number of crises | no estimate extracted | 1 study · 145 participants | Moderate Downgraded: risk of bias, imprecision |
Red blood cell dehydration | no estimate extracted | 3 studies · 524 participants | Very low Downgraded: risk of bias, imprecision |
Quality of life: Days of work lost per crisis | no estimate extracted | 1 study · 145 participants | Moderate Downgraded: risk of bias, imprecision |
Number of other sickle‐related events: | no estimate extracted | 1 study · 90 participants | Low Downgraded: risk of bias, imprecision |